Type 2 diabetes mellitus (T2DM) is increasingly viewed beyond a metabolic disorder, with a growing focus on microbiome-related mechanisms. A review published in Acta Diabetologica examined how gut microbiota contribute to disease variability and how this knowledge may support precision-based approaches in T2DM management.

The review synthesized current evidence on gut microbial dysbiosis and integrated newer insights on microbial metabolites, strain-specific effects, and host–microbe–drug interactions. Particular attention was given to the influence of commonly used therapies such as metformin on microbial composition, along with the potential role of specific organisms such as Akkermansia muciniphila. The analysis also outlined emerging domains, including the gut virome, microbial gene editing, and targeted modulation of short-chain fatty acids.

The findings highlighted a shift from descriptive associations toward individualized therapeutic approaches. The review proposed a framework that considers gut microbiota as a dynamic and modifiable factor in T2DM care. It also emphasized the need for standardized methodologies, integration of multi-omics data, and cross-disciplinary clinical studies to support translation into clinical practice.

These insights suggest that microbiome-focused strategies may contribute to more personalized approaches in T2DM, although further clinical validation is required.